Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
FENOPROFEN CALCIUM vs KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Category C
Category D/X
NSAID
NSAID